Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,505
  • Shares Outstanding, K 3,540
  • Annual Sales, $ 810 K
  • Annual Income, $ -10,170 K
  • 60-Month Beta 1.52
  • Price/Sales 10.33
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade CANF with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.37
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +75.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +9.50%
on 02/20/24
2.25 -2.67%
on 03/14/24
+0.11 (+5.45%)
since 02/16/24
3-Month
1.87 +17.11%
on 01/19/24
2.27 -3.52%
on 01/30/24
+0.13 (+6.31%)
since 12/18/23
52-Week
1.52 +44.08%
on 04/12/23
3.33 -34.23%
on 06/15/23
-0.08 (-3.52%)
since 03/17/23

Most Recent Stories

More News
Happy Thanksgiving, Uncle Sam!

Monday U.S. Economic Lookahead U.S. leading economic indicators (Oct.) Featured Earnings Agilent ...

WN.TO : 180.06 (-0.06%)
A : 146.09 (-0.94%)
TCOM : 44.25 (+1.91%)
KEYS : 149.71 (-0.06%)
NVDA : 884.55 (+0.70%)
LOW : 243.48 (-0.51%)
MDT : 83.66 (+0.11%)
DE : 385.31 (+0.50%)
GDS : 7.67 (+1.32%)
BMA : 45.63 (+4.90%)
HTHT : 39.00 (-0.23%)
LEXX : 3.40 (-12.82%)
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy

Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CANF : 2.19 (+3.30%)
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

CANF : 2.19 (+3.30%)
BMY : 51.59 (-1.43%)
LLY : 762.66 (+1.13%)
MRK : 121.44 (-0.07%)
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.19 (+3.30%)
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.19 (+3.30%)
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.19 (+3.30%)
Can-Fite Reports 2022 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.19 (+3.30%)
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.19 (+3.30%)
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.19 (+3.30%)
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CFBI : 10.08 (-0.30%)
CANF : 2.19 (+3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

3rd Resistance Point 2.41
2nd Resistance Point 2.30
1st Resistance Point 2.25
Last Price 2.19
1st Support Level 2.09
2nd Support Level 1.98
3rd Support Level 1.92

See More

52-Week High 3.33
Fibonacci 61.8% 2.64
Fibonacci 50% 2.42
Fibonacci 38.2% 2.21
Last Price 2.19
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar